Determination of Biological Age: Geriatric Assessment vs Biological Biomarkers

Lucas W. M. Diebel,Kenneth Rockwood

DOI: https://doi.org/10.1007/s11912-021-01097-9

2021-07-16

Current Oncology Reports

Abstract:<span class="a-plus-plus abstract-section id-a-sec1"><h3 class="a-plus-plus">Purpose of Review</h3><p class="a-plus-plus">Biological age is the concept of using biophysiological measures to more accurately determine an individual's age-related risk of adverse outcomes. Grading of the degree of frailty and measuring biomarkers are distinct methods of measuring biological age. This review compares these strategies for estimating biological age for clinical purposes.</p></span><span class="a-plus-plus abstract-section id-a-sec2"><h3 class="a-plus-plus">Recent Findings</h3><p class="a-plus-plus">The degree of frailty predicts susceptibility to adverse outcomes independently of chronological age. The utility of this approach has been demonstrated across a range of clinical contexts. Biomarkers from various levels of the biological aging process are improving in accuracy, with the potential to identify aberrant aging trajectories before the onset of clinically manifest frailty.</p></span><span class="a-plus-plus abstract-section id-a-sec3"><h3 class="a-plus-plus">Summary</h3><p class="a-plus-plus">Grading of frailty is a demonstrably, clinically, and research-relevant proxy estimate of biological age. Emerging biomarkers can supplement this approach by identifying accelerated aging before it is clinically apparent. Some biomarkers may even offer a means by which interventions to reduce the rate of aging can be developed.</p></span>

oncology